Lenalidomide 5 Mg Capsule Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 5mg
Reference Brands: Lenalid
Category:
Orphan Drugs
Lenalidomide is used to treat anemia (low red blood cells) in patients with a certain type of myelodysplastic syndrome (MDS). Patients with MDS may have very low red blood cell counts and require blood transfusions.
Lenalidomide 5 mg Capsule is available in Capsules
and strengths such as 5mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lenalidomide 5 mg Capsule is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lenalidomide 5 mg Capsule can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lenalidomide is an immunomodulatory and antineoplastic agent widely used in the treatment of hematological malignancies. It is marketed globally under the brand name Revlimid, along with several approved generic versions. Lenalidomide is primarily indicated for the treatment of multiple myeloma, where it is used as a first-line therapy in combination with dexamethasone, as well as in relapsed or refractory disease settings.
In addition to multiple myeloma, lenalidomide is used for the treatment of smoldering multiple myeloma, certain indolent non-Hodgkin lymphomas, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and myelodysplastic syndromes (MDS), particularly those associated with deletion 5q cytogenetic abnormality. The drug works through multiple mechanisms, including immune modulation, inhibition of tumor cell proliferation, and suppression of angiogenesis.
Due to its potent therapeutic effects and safety considerations, lenalidomide is subject to strict prescribing and monitoring requirements in many countries. It remains a cornerstone therapy in modern hematology and oncology treatment protocols worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing